New pancreatic cancer combination therapy shows promise in clinical trial

Researchers have identified a five-plus-three drug regimen that improves outcomes for pancreatic cancer patients, according to a study published in Clinical Cancer Research. The finding could reshape treatment protocols and expand the market for combination therapies in one of oncology's most lethal cancers.

Originaltitel: Five plus Three for the Pancreas